Global Phenylketonuria Therapeutic Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Phenylketonuria Therapeutic Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Phenylketonuria (PKU) is an inborn error of metabolism that results in decreased metabolism of the amino acid phenylalanine. Untreated PKU can lead to intellectual disability, seizures, behavioral problems, and mental disorder. It may also result in a musty smell and lighter skin. Babies born to mothers who have poorly treated PKU may have heart problems, a small head, and low birth weight.
Phenylketonuria Therapeutic report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Phenylketonuria Therapeutic market is projected to reach US$ 1783.2 million in 2029, increasing from US$ 1000 million in 2022, with the CAGR of 8.6% during the period of 2024 to 2029. Demand from Household and Hospital are the major drivers for the industry.
The phenylketonuria (PKU) therapeutic market is primarily driven by the increasing prevalence of PKU and the growing demand for effective treatments to manage this rare genetic disorder. PKU is characterized by the inability to metabolize the amino acid phenylalanine, leading to its accumulation in the body, which can cause severe neurological and cognitive impairments if left untreated. As awareness about PKU and newborn screening programs improve, more patients are being diagnosed early, increasing the need for therapeutic interventions. However, the market also faces challenges, including the complexity of managing PKU through dietary restrictions and adherence to low-phenylalanine diets. This can be particularly challenging for young children and adults, impacting their quality of life and nutritional intake. Moreover, the limited availability of novel and more effective treatments for PKU poses a hurdle in addressing the unmet medical needs of patients. Addressing these challenges requires continued research and development of innovative therapies, including enzyme replacement therapies, gene therapies, and pharmacological interventions, to improve PKU management and alleviate dietary burdens. Additionally, raising awareness about PKU and its consequences among healthcare professionals and the general public is essential to facilitate early diagnosis and access to appropriate therapeutic options, ultimately driving the growth of the phenylketonuria therapeutic market and improving patient outcomes.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Phenylketonuria Therapeutic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Biomarin
Mead Johnson
Abbott
Nutricia
Dr. Schär
Vitaflo
Cambrooke
PKU Perspectives
Firstplay Dietary
Segment by Type
Medications
Supplements
Household
Hospital
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Phenylketonuria Therapeutic market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Phenylketonuria Therapeutic introduction, etc. Phenylketonuria Therapeutic Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Phenylketonuria Therapeutic market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Phenylketonuria Therapeutic report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Phenylketonuria Therapeutic market is projected to reach US$ 1783.2 million in 2029, increasing from US$ 1000 million in 2022, with the CAGR of 8.6% during the period of 2024 to 2029. Demand from Household and Hospital are the major drivers for the industry.
The phenylketonuria (PKU) therapeutic market is primarily driven by the increasing prevalence of PKU and the growing demand for effective treatments to manage this rare genetic disorder. PKU is characterized by the inability to metabolize the amino acid phenylalanine, leading to its accumulation in the body, which can cause severe neurological and cognitive impairments if left untreated. As awareness about PKU and newborn screening programs improve, more patients are being diagnosed early, increasing the need for therapeutic interventions. However, the market also faces challenges, including the complexity of managing PKU through dietary restrictions and adherence to low-phenylalanine diets. This can be particularly challenging for young children and adults, impacting their quality of life and nutritional intake. Moreover, the limited availability of novel and more effective treatments for PKU poses a hurdle in addressing the unmet medical needs of patients. Addressing these challenges requires continued research and development of innovative therapies, including enzyme replacement therapies, gene therapies, and pharmacological interventions, to improve PKU management and alleviate dietary burdens. Additionally, raising awareness about PKU and its consequences among healthcare professionals and the general public is essential to facilitate early diagnosis and access to appropriate therapeutic options, ultimately driving the growth of the phenylketonuria therapeutic market and improving patient outcomes.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Phenylketonuria Therapeutic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Biomarin
Mead Johnson
Abbott
Nutricia
Dr. Schär
Vitaflo
Cambrooke
PKU Perspectives
Firstplay Dietary
Segment by Type
Medications
Supplements
Segment by Application
Household
Hospital
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Phenylketonuria Therapeutic market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Phenylketonuria Therapeutic introduction, etc. Phenylketonuria Therapeutic Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Phenylketonuria Therapeutic market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices